Exosomes from Musely are being discussed as a topical hairlosstreatment containing ingredients like latanoprost, caffeine, cetirizine, melatonin, vitamin D3, vitamin E, and biotin. Users are curious about its effectiveness and potential side effects, noting it may take 4-6 months to see results.
The conversation discusses the delay in the release of a new hairlosstreatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.
Alfatradiol is used as a mild treatment to slow or stabilize hairloss, often alongside finasteride and pumpkin seed oil. Users report reduced shedding and minimal side effects, but minoxidil is noted as more effective for regrowth.
Pelage Pharmaceuticals raised $120M for their hairlosstreatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
Mixing tretinoin into minoxidil foam is being considered to simplify a hairlosstreatment routine. The current regimen includes oral dutasteride, topical tretinoin, topical minoxidil, and fluridil.
An 18-year-old is using a high-dose hairlosstreatment with 40mg daily dutasteride, finasteride, minoxidil, tretinoin, and topical bicalutamide. Despite health risk concerns, especially liver issues, they report hair regrowth progress and intend to continue the regimen.
The user is considering whether to continue their hairlosstreatment, which includes finasteride, minoxidil spray, keto shampoo, and dermarolling. Suggestions include increasing minoxidil application, adding multivitamins, improving sleep, and possibly switching to dutasteride, while the consensus is to keep going with the treatment.
A user shared a 1-year progress on hairlosstreatment using 0.5mg of oral finasteride and 5mg of oral minoxidil, showing significant hair regrowth from almost bald to much thicker hair. Other users discussed their own experiences with these treatments, with some preferring topical applications to avoid side effects.
A user's one-year progress in hairlosstreatment using finasteride and minoxidil. The user shared their experience and advice, including adjusting the amount of sprays used based on individual needs and the importance of patience and positivity in the process.
A user shared a 1.5-year hairlosstreatment progress using 1mg Finasteride and 5% Minoxidil, planning to switch to oral Minoxidil and considering adding RU58841. They saw gradual improvement, suspecting Finasteride as the main contributor since they might not respond to topical Minoxidil.
Automatic-Law-3612's progress with hairlosstreatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.
The conversation is about creating a higher concentration of the newly FDA-approved hairlosstreatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.
The post discusses using Sandalore as a potential hairlosstreatment, emphasizing precise measurements and safe handling. The user compares Sandalore's effects to Minoxidil and mentions preparing a solution with ethanol and DMSO.
The conversation is about a user trying a 0.2% Alfatrafiol treatment for hairloss, combined with Kx826, Minoxidil, microneedling, and ketoconazole. The user reports reduced itching and discusses sourcing the treatment.
Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hairloss, with mixed user experiences. Some users report no results, while others find it mildly effective.
RU58841 is discussed as a potential treatment for acne and hairloss, with users debating its effectiveness and safety compared to other treatments like finasteride, minoxidil, and dutasteride. Concerns about RU58841's side effects and lack of clinical trials are raised, while some users share their personal experiences and routines involving RU58841 for hairloss.
A user is testing clascoterone (Winlevi) on their scalp for hairloss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.
CB 03 01 (Breezula) was tried for hairloss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.
The conversation discusses using crushed finasteride tablets mixed with topical minoxidil for hairlosstreatment. Users share their experiences and opinions on the effectiveness and proper concentration of this method.
Clascoterone is being discussed for hairloss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hairloss.
Finasteride and dutasteride can cause psychiatric side effects like depression and suicidal thoughts in some users, especially those with a history of mental health issues. While some users experience positive hair growth results, others face severe psychological effects, raising concerns about their safety and the need for careful monitoring.
The user is experiencing significant hairloss after switching from finasteride to dutasteride for five months. Suggestions include that the hairloss might be a normal shedding phase, with some recommending continuing the treatment for up to 24 months or considering alternatives like RU58841.
The user noticed a significant improvement in hairloss after 3.5 months using a topical treatment of 7% Minoxidil, 0.1% Finasteride, and 0.025% Tretinoin, which was prescribed and shipped from a pharmacy in Indiana. Other users discussed alternative products with varying concentrations of Minoxidil and Finasteride.
The user saw no hairloss improvement for a year using 1mg finasteride and 5% minoxidil. They experienced better results after reducing finasteride to 0.25mg, adding a derma pen treatment, and applying a solution with minoxidil and melatonin.
Pyrilutamide, a possible hairlosstreatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
The conversation discusses the progress of Clascoterone (Breezula) for hairlosstreatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
The conversation discusses transitioning from topical to oral minoxidil for hairlosstreatment and explores the potential use of Aminexil, despite concerns about its effectiveness compared to minoxidil. It highlights the risks and side effects of oral minoxidil, such as potential heart and liver damage, and emphasizes the importance of monitoring blood pressure.
The user discusses their hair regrowth success with minoxidil, red light therapy, massage, and derma stamping but expresses concerns about using finasteride due to potential side effects. They are interested in using clascoterone as a topical treatment for hairloss and are exploring the possibility of creating a topical formula from raw clascoterone powder.
Finasteride is effective for hairloss but can cause sexual dysfunction and mental health issues in some users, leading to a polarized debate on its risks. Some switch to alternatives like Dutasteride or topical treatments to avoid side effects.